ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Megestrol Acetate

Also written as “Nano-crystalline Megestrol Acetate Oral Suspension”, “Megestrol acetate concentrated suspension 125 mg/mL” and “Megestrol acetate”.

Its studies are mostly in Anorexia · Cachexia · Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis, led by 6 companies.

Drug pageMegestrol Acetate: every studyMany companies study it; this page follows only the 18 they lead. All 66 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 15, 202518 company-led studies, 7 open or runningNext primary completion: Dec 31, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceuticalits history only77 open or runningphase 4since Nov 15, 2025Dec 25, 2024Dec 31, 2026phase 4 · NCT07243379
Bristol-Myers Squibbits history only30 open or runningphase 4since Nov 2, 1999Nov 2, 1999none ahead
Par Healthits history only30 open or runningphase 3since Mar 11, 2008Mar 11, 2008none ahead
Keenova Therapeuticsits history only20 open or runningphase 2since Mar 11, 2008Mar 11, 2008none ahead
Rottapharm Spainits history only20 open or runningphase 3since Jul 17, 2007Jul 17, 2007none ahead
TTY Biopharm10 open or runningphase 2since Jul 25, 2016Jul 25, 2016none ahead

Also a collaborator on its studies: Quintiles, Covance, SFBC Anapharm and PRA Health Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 25, 2016First study: phase 2 study in Head and Neck NeoplasmsFirst studyNCT02980653 · 105 enrolled · Taiwan

TargetBeta

PGR →read by rule
“Progesterone receptor agonist”ChEMBL 37, by rule

Other programs on PGR

ProgramCompanyFurthest phaseStudies
LevonorgestrelruleBayerphase 456
drospirenoneruleestetraphase 420
Medroxyprogesterone AcetaterulePfizerphase 411
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Utrogestanrulecalla-lily-clinical-care-ltdphase 11

Studies

The one study TTY Biopharm leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02980653Head and Neck Neoplasms · Taiwan2UNKNOWNAug 2017105

How it is read

Names in the registry

  • “Nano-crystalline Megestrol Acetate Oral Suspension”, 5 entries
  • “Megestrol acetate concentrated suspension 125 mg/mL”, 5 entries
  • “Megestrol acetate”, 5 entries
  • “Nanocrystalline Megestrol Acetate”, 2 entries
  • “Megestrol acetate concentrated suspension 110 mg/mL”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.